We’re attending SLAS 25
Meet us on January 25-29, San Diego Convention Center San Diego, CA (USA). Don’t miss our poster presentation: Title: Enhancing degrader research with CETSA.Date: January 28thTime: 2:00–3:00 pm Meet o...
We’re attending MSD Technology Symposium
Meet us on September 24-25, Greater Philadelphia Expo Center, Oaks, PA (US). New service Learn more about or latest contribution to our service portfolio; Standard Selectivity Profiling, by attending ...
We’re attending BPS New Therapeutic Modalities 2025
Pelago Bioscience is attending New Therapeutic Modalities: Transforming Receptor Pharmacology, hosted by the British Pharmacological Society, on April 2–3 in Cambridge, UK. This event will bring toget...
Webinar: Applying CETSA® to Translational Studies – A Sitryx Story
Bridging the Gap Between In Vitro and In Vivo with CETSA 4 March 2025 17:00 CET | 16:00 GMT | 11:00 EST | 08:00 PST Missed the Webinar? We’ve Got You Covered! Translating early drug discovery in...
Unlocking Proteomics: Pelago Bioscience’s HUPO Award-Winning CETSA® approach
Stockholm, Sweden 12 September 2023 Pelago Bioscience proudly receives the HUPO Science and Technology Award, celebrating our pioneering work in CETSA (Cellular Thermal Shift Assay) and the Pelago tea...
University of Southampton acknowledges Pelago Bioscience’s patent and use of CETSA® process
Pelago Bioscience is excited about University of Southampton researchers, led by Professor Tavassoli, having found our patented CETSA® technology useful in their research into identifying hypoxia-indu...
University of Edinburgh acknowledges Pelago Bioscience’s patent and use of CETSA® process
In connection with the CETSA platform, the University of Edinburgh states: “The University of Edinburgh wishes to acknowledge the validity of Pelago’s CETSA patent (EP 2 699 910 B1) entitled “Methods ...
The Koehler Lab at MIT acknowledges Pelago Bioscience’s patent and use of CETSA® process
Pelago Bioscience celebrates that the Koehler Lab at the Massachusetts Institution of Technology found CETSA® to be a valuable method for quantifying drug Target Engagement in the lab’s experiments de...
Pelago Bioscience showcases at AACR 2025
April 25–30, 2025 | Chicago, IL | Booth #1656 Pelago Bioscience is exhibiting at the AACR Annual Meeting 2025, where oncology and drug discovery professionals gather to share the latest scientif...
Pelago Bioscience presents at LRIG Philadelphia Annual Vendor Exhibition
Pelago Bioscience is proud to participate in the LRIG Philadelphia Annual Vendor Exhibition. This event brings together scientists, researchers, and technology leaders to explore the latest innovation...
Pelago Bioscience Featured in Top Ten Most Popular Drug Hunter Resources of 2023
We’re delighted to share that our commitment to advancing Drug Discovery has earned us a spot in the “Top Ten Most Popular Drug Hunter Resources of 2023.” The insightful article, “Drug Target Identifi...
Pelago Bioscience at SLAS Europe 2025
May 20-22, 2025 | Hamburg, Germany Pelago Bioscience is excited to announce our participation in SLAS Europe 2025 in Hamburg, Germany, from May 20-22. As a leading provider of innovative solutions for...
Pelago Bioscience at Oxford Global Discovery & Development Europe 2025
June 23-24, 2025 | Basel, Switzerland Pelago Bioscience is proud to sponsor and exhibit at Oxford Global Discovery & Development Europe 2025, June 23–24, at the Congress Centre Basel. This influen...
Pelago Bioscience AB signs strategic agreement with Cancer Research Horizons
Pelago Bioscience AB signs a strategic agreement with Cancer Research Horizons to unlock quantitative assessment of cellular target engagement across its pipeline of novel oncology programmes. The com...
New privacy policy
We respect your integrity and ensure that your personal data is processed with the confidentiality and respect that is required. Therefore, We have revised our privacy policy.
New CETSA® Publication
Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applications In a recent collaboration between AbbVie Chemical...